Two distinct signalling pathways are involved in the control of the biphasic junB transcription induced by interleukin-6 in the B cell hybridoma 7TD1.
We have measured the level of junB mRNA in the B hybridoma cell line 7TD1, under interleukin-6 (IL-6) stimulation. IL-6 increases junB mRNA in a biphasic fashion. The first early-induced peak was transient and likely corresponds to the well documented typical junB mRNA, stimulated in response to numerous growth factors, including IL-6. At variance, the second peak which has never been reported previously, lasted several hours. As a consequence of its effect on junB mRNA, IL-6 stimulated, in a biphasic fashion, the nuclear accumulation of the JunB protein. In this study, we demonstrated that IL-6 regulation occurred exclusively at the transcriptional level and that the bimodal increase of junB mRNA and JunB protein can be accounted for by a biphasic stimulation of junB transcription. Furthermore, our data point to two major differences between the mechanism of control of the early and the late IL-6-induced junB transcription waves. First, cycloheximide strongly potentiated the transcription of the second wave, whereas it failed to affect the early-induced burst. Second, tyrphostin, a tyrosine kinase inhibitor, impaired the expression of the first but not the second junB mRNA peak. Conversely, genistein, another tyrosine kinase inhibitor, totally abolished the expression of the second peak of junB mRNA whereas it did not affect the expression of the first peak. Altogether these data indicate that, in 7TD1 cells, IL-6 controls junB transcription in a biphasic fashion by means of two separate transduction pathways.
Rezzonico
R
R
INSERM U364, Faculté de Médecine, Nice, France.
Ponzio
G
G
Loubat
A
A
Lallemand
D
D
Proudfoot
A
A
Rossi
B
B
D001402:B-Lymphocytes / Q000378:metabolism*; D002396:Catechols / Q000494:pharmacology; D002460:Cell Line; D003513:Cycloheximide / Q000494:pharmacology; D019833:Genistein; D006801:Humans; D006825:Hybridomas; D015850:Interleukin-6 / Q000494:pharmacology*; D007529:Isoflavones / Q000494:pharmacology; D009570:Nitriles / Q000494:pharmacology; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D016755:Proto-Oncogene Proteins c-jun / Q000235:genetics*; D012333:RNA, Messenger / Q000378:metabolism; D015398:Signal Transduction; D014158:Transcription, Genetic; D020032:Tyrphostins
D002396:Catechols; D015850:Interleukin-6; D007529:Isoflavones; D009570:Nitriles; D016755:Proto-Oncogene Proteins c-jun; D012333:RNA, Messenger; D020032:Tyrphostins; C060152:tyrphostin 47; D003513:Cycloheximide; D019833:Genistein; D011505:Protein-Tyrosine Kinases